5th How to Diagnose and Treat Lymphoma

October 29-31, 2026 - Prague, Czech Republic

Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont

Thursday, October 29, 2026

08:35-08:45 Welcome

SESSION I – Follicular lymphoma
Chair: Christian Buske (Ulm)

08:45-09:20 DEBATE 1 - Do we need (at all) T-cell engagers in the first line management of follicular lymphoma?

Audience votes

08:45-09:00 YES — Georg Hess (Mainz)

09:00-09:15 NO — Maria Gomes da Silva (Lisbon)

09:15-09:20 *Discussion*

Audience votes again

09:20-09:40 Case-based lecture: Managing (first) relapse: Role of ASCT in the era of Tafa/R2 and immunotherapies — Clémentine Sarkozy (Saint-Cloud)
09:40-09:45 *Discussion*

09:45-10:05 Case-based lecture: Rare subtypes of follicular lymphoma — Oliver Weigert (Munich)
10:05-10:10 *Discussion*

10:10-10:15 *Selected brief oral communication*
Safety and efficacy of subcutaneous mosunetuzumab plus lenolidomide induction therapy followed by mosunetuzumab maintenance in previously untreated follicular lymphoma — *Ángel Serna Pareja (Barcelona)*
10:15-10:18 Discussion

10:18-10:40 Panel discussion

10:40-11:10 Coffee Break

SESSION II – T-cell lymphoma
Chair: Alison J. Moskowitz (New York)

11:10-11:25 Interactive case: Current approaches to diagnose nodal T-cell lymphoma entities — Laurence de Leval (Lausanne)
11:25-11:30 *Discussion*

11:30-11:50 Case-based lecture: First-line treatment — Alison J. Moskowitz (New York)
11:50-11:55 *Discussion*

11:55-12:15 Case-based lecture: Extra nodal T-cell — Philippe Gaulard (Créteil)
12:15-12:20 *Discussion*

12:20-12:40 Case-based lecture: New drugs — Eric Jacobsen (Boston)
12:40-12:45 *Discussion*

12:45-13:15 Panel discussion

13:15-15:10 Lunch

14:00-15:00 SATELLITE SYMPOSIUM
Redefining Care in B-Cell Malignancies: Integrating Innovation into Clinical Practice
Chair: Clémentine Sarkozy (Paris)
Speakers: Anna Maria Frustaci (Milan), Clémentine Sarkozy (Paris), Fernando Martín Moro (Madrid)

This symposium is organised and sponsored by BeOne

SESSION III – Mantle cell lymphoma
Chair: Clémentine Sarkozy (Saint-Cloud)

15:10-15:25 Interactive case: Do we need still chemo first line? — Clémentine Sarkozy (Saint-Cloud)
15:25-15:30 *Discussion*

15:30-15:50 Case-based Lecture: — Simone Ferrero (Torino)
Optimal approach of cBTKi exposed relapsing MCL
(approval of Pirto, CAR-T maturing data, bi-specifics emerging)
15:50-15:55 *Discussion*

15:55-16:15 Case-based lecture: — Sara Ek (Lund)
Should we adapt treatment according to biological characteristics?
16:15-16:20 *Discussion*

16:20-16:25 Selected brief oral communication
Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study — *Wojciech Jurczak (Krakow)*
16:25-16:28 Discussion

16:28-16:50 Panel discussion

16:50-17:20 Coffee break

17:20-18:00 DEBATE 2 – Transplant in B-cell lymphoma in 2026
Chair: Michael Crump (Toronto), Catherine Thieblemont (Paris)

17:20-17:45 Overview of the change in paradigm of patients with RR DLBCL — Andrew Davies (Southampton)

17:45-17:50 *Discussion and Interaction*

17:50-18:00 Debate

18:00-18:40 ROUNDTABLE 1 – TOX and PRO
Chair: Andrew Davies (Southampton)

18:00-18:15 Evaluation of toxicity and tolerability in lymphoma clinical trials — Gita Thanarajasingam (Rochester)

18:15-18:30 Evaluation of new drugs safety — Tarec Christoffer El-Galaly (Aarhus)

18:30-18:40 *Discussion*

18:45-20:15 ***Poster Walks and Welcome Get Together***
Biology Poster Walk Leaders: Oliver Weigert (Munich), Laurence de Leval (Lausanne)
Clinical Poster Walk Leaders: Sara Ek (Lund)*, Andrew Davies (Southampton)*

Friday, October 30, 2026

09:00-10:00 3 Simultaneous Meet the Expert sessions

1. Lymphoma classification: WHO5, ICC and beyond — Laurence de Leval (Lausanne)
2. Improving CAR T-cell outcomes for B-cell lymphoma — Gloria Iacoboni (Barcelona)
3. PET and its role in B-cell lymphomas — Andrew Davies (Southampton)

10:00-10:30 Coffee Break

SESSION IV – Diffuse large B-cell lymphoma
Chair: Bjoern Chapuy (Berlin)

10:30-10:45 Interactive case: Management of elderly patients with diffuse large B-cell lymphoma — Bjoern Chapuy (Berlin)
10:45-10:50 *Discussion*

10:50-11:10 Case-based lecture: First-line — Maria Gomes da Silva (Lisbon)
11:10-11:15 *Discussion*

11:15-11:35 Case-based lecture: Current standards at first relapse for diffuse large B-cell lymphoma — Marek Trneny (Prague)
11:35-11:40 *Discussion*

11:40-12:00 Case-based lecture: Patient selection for second-line therapy — Gloria Iacoboni (Barcelona)
12:00-12:05 *Discussion*

12:05-12:10 *Selected brief oral communication*
Total metabolic tumor volume and circulating tumor DNA as early prognostic factors in relapsed/refractory Diffuse Large B-cell Lymphoma: Results from the Phase 3 STARGLO trial — *Charles Herbaux (Montpellier)*
12:10-12:13 Discussion

12:13-12:35 Panel discussion

12:35-13:50 Lunch

13:50-14:45 ROUNDTABLE 2 – Current immunotherapy
Chair: Catherine Thieblemont (Paris)

13:50-14:05 CAR-T cells: New paradigms in B-cell lymphomas — Gloria Iacoboni (Barcelona)

14:05-14:20 Bispecific antibodies used as single agent: State of the art — Sarit Assouline (Montreal)

14:20-14:35 Bispecific combinations and future developments — Marion Subklewe (Munich)

14:35-14:45 *Discussion*

14:45-15:25 DEBATE 3 – Chronic lymphocytic leukaemia
Chair: Sarit Assouline (Montreal)

Audience votes

14:45-15:00 Fixed duration treatment — Barbara Eichhorst (Cologne)

15:00-15:15 Continuous treatment or MRD guided treatment — Talha Munir (Leeds)

15:15-15:25 *Discussion*

Audience votes again

15:25-15:55 Coffee break

SESSION V – Non-follicular indolent B-cell lymphomas
Chair: Christian Buske (Ulm)

15:55-16:10 Interactive case: Marginal zone lymphoma management of the relapsed/refractory patient — Catherine Thieblemont (Paris)
16:10-16:15 *Discussion*

16:15-16:35 Case-based lecture: Waldenström Macroglobulinemia management of the relapsed/refractory patient — Anna Maria Frustaci (Milan)
16:35-16:40 *Discussion*

16:40-17:00 Case-based lecture: Hairy cell leukaemia: Recent advances in understanding and management — Brunangelo Falini (Perugia)
17:00-17:05 *Discussion*

17:05-17:25 Case-based lecture: Transformation of indolent lymphomas – Biology, diagnostics and grey zones — Wolfram Klapper (Kiel)
17:25-17:30 *Discussion*

17:30-17:35 *<u>Selected brief oral communication</u>*
Long-term efficacy of vemurafenib (VEM) + rituximab (RTX) in patients (pts) with relapsed/refractory (R/R) hairy cell leukemia (HCL) enrolled in the HCL-PG03 phase-2 academic trial — *Alessandro Mancini (Perugia)*
17:35-17:38 *Discussion*

17:38-18:00 *Panel discussion*

Saturday, October 31, 2026

08:30-09:30 3 Simultaneous Breakfast Meet the Expert Sessions
1. Diffuse large B-cell lymphoma — Bjoern Chapuy (Berlin)

	2. Follicular lymphoma	Oliver Weigert (Munich)
	3. T-cell lymphoma	Eric Jacobsen (Boston), Alison J. Moskowitz (New York)

09:30-10:00 Coffee break

SESSION VI – Hodgkin lymphoma
Chair: Alison J. Moskowitz (New York)

10:00-10:15	Interactive case: Nodular lymphocyte predominant Hodgkin lymphoma	Dennis Eichenauer (Cologne)
10:15-10:20	*Discussion*	
10:20-10:40	Case-based lecture: Elderly patients	Vittorio Ruggero Zilioli (Milan)
10:40-10:45	*Discussion*	
10:45-11:05	Case-based lecture: First-line treatment for younger patients	Michael Crump (Toronto)
11:05-11:10	*Discussion*	
11:10-11:30	Case-based lecture: Relapse	Marc André (Yvoir)
11:30-11:35	*Discussion*	
11:35-11:40	*Selected brief oral communication* *Mendelian Randomization reveals the causative role of genetically predicted viral Infection in pan-lymphoma risk*	*Haiwen Huang (Suzhou)*
11:40-11:43	*Discussion*	
11:43-12:05	*Panel discussion*	

12:05 -12:35 Keynote lecture
Chair: Michael Crump (Toronto)

12:05-12:25	Artificial Intelligence: Impact on lymphoma care	Anthony Mato (New York)
12:25-12:35	*Discussion*	

12:35-12:45 Closing remarks

MEETING CLOSURE